Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brad Prybis

Orthopaedic Surgery of the Spine Stockbridge, GA Medical Doctor

NPI 1245296391 CMS profile 237401

135 N Park Pl Ste 101, Ste A1, Stockbridge, GA 30281

Open in the dashboard

General payments

$658,786

828 records reported · program years 2019–2025

Research payments

$154,500

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$818,202

7 holdings reported · through program year 2025

Research they led as principal investigator

$1,045 paid to institutions, not to them · program year 2019

Through program year 2025, Brad Prybis of Stockbridge, GA is reported in the CMS Open Payments database as having received $658,786 across 828 general payments and $154,500 in research payments paid to them. Separately, studies naming them as principal investigator received $1,045 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $818,202 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

19 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59,865 102
2024 General $77,629 162
2023 General $66,185 104
2023 Research $27,750 2
2022 General $73,784 105
2022 Research $39,000 6
2021 General $149,107 170
2021 Research $13,750 4
2020 General $82,887 76
2020 Research $27,000 1
2019 General $149,329 109
2019 Research $47,000 1
2025 Ownership $131,897 1
2024 Ownership $126,897 1
2023 Ownership $121,884 1
2022 Ownership $116,884 1
2021 Ownership $111,884 1
2020 Ownership $106,885 1
2019 Ownership $101,871 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brad Prybis
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Brad Prybis were reported at $59,865. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Brad Prybis Orthopaedic Surgery of the Spine median Middle half National median
2019 $149,329 $2,106 $337–$18,608 $163
2020 $82,887 $1,213 $156–$15,082 $114
2021 $149,107 $1,834 $271–$15,617 $132
2022 $73,784 $2,015 $320–$17,036 $149
2023 $66,185 $1,925 $336–$14,599 $160
2024 $77,629 $2,110 $341–$12,483 $164
2025 $59,865 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $176,075 90 payments
  2. Royal Biologics $168,910 58 payments
  3. Stryker Corporation $123,162 175 payments
  4. 4WEB, Inc. $116,580 409 payments
  5. Medical Investment Advisors LLC $26,881 13 payments
  6. Spineart SA $23,557 12 payments
  7. Intelivation Technologies, LLC $11,125 5 payments
  8. Spineart USA Inc $6,656 12 payments
  9. MiRus, LLC $2,655 1 payment
  10. Orthofix Medical, Inc. $928 6 payments
  11. Other $2,258 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $319,130 70 payments
  2. Consulting Fee $231,388 93 payments
  3. Travel and Lodging $59,716 95 payments
  4. Food and Beverage $30,618 562 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,831 5 payments
  6. Entertainment $104 3 payments
Products named General payments · program years 2019–2025
  1. SPINE TRUSS SYSTEM $116,580 409 payments
  2. XTEND Spine $84,519 6 payments
  3. ES2 SPINAL SYSTEM $37,229 14 payments
  4. XTEND Spine/Joint $33,958 4 payments
  5. TRITANIUM Hips $26,325 4 payments
  6. TRITANIUM Hips $25,831 30 payments
  7. AIRO $20,278 5 payments
  8. EVEREST SPINAL SYSTEM $19,569 5 payments
  9. ALTERA $18,350 5 payments
  10. PERLA C $17,521 3 payments
  11. Other $240,238 318 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Smart-Surgical Inc. dba Burst Biologics $77,500 3 payments
  2. Royal Biologics $77,000 11 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,016

Median for Orthopedic Surgery: 203

Drug cost

$8,849

Median for Orthopedic Surgery: $1,433

Branded share of claims

22.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 297 $2,186
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 160 $1,787
Methocarbamol Generic 96 $950
Acetaminophen-Codeine Acetaminophen With Codeine Brand 39 $659
Diclofenac Sodium Generic 39 $612
Tizanidine Hcl Generic 60 $538
Promethazine Hcl Generic 75 $417
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $367
Pregabalin Generic 33 $319
Cyclobenzaprine Hcl Generic 36 $289

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$165,166

Of which drugs: $276

Medicare patients

164

Average age 72

Services billed

3,185

86 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 41%
Chronic kidney disease 30%
Ischemic heart disease 27%
Depression 21%
COPD 20%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 2,181 $221
Injection, ketorolac tromethamine, per 15 mg J1885 Office 14 26 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

842 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record